An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia

Trial Profile

An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Romyelocel-L (Primary) ; Filgrastim
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Cellerant Therapeutics
  • Most Recent Events

    • 23 Mar 2017 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018.
    • 23 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2018.
    • 30 Jan 2017 Planned number of patients changed from 146 to 160.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top